Abstracts tagged "Osteoarthritis"

Abstract Number: 0220 • ACR Convergence 2021
Relation of Knee Extensor Power to Worsening Cartilage Damage in the Knee: The MOST Study
Joshua Stefanik¹, David Felson², Cara Lewis³, Gabriela Rabasa², Ali Guermazi², Frank Roemer⁴, Michael Nevitt⁵, Cora Lewis⁶ and Neil Segal⁷, ¹Northeastern University, Boston, MA, ²Boston University, Boston, MA, ³Boston University, Brookline, MA, ⁴Friedrich-Alexander University Erlangen-Nurnberg, Erlangen, Germany, ⁵University of California San Francisco, Orinda, CA, ⁶University of Alabama Birmingham, Birmingham, AL, ⁷University of Kansas Medical Center, Iowa City, IA
Background/Purpose: The relation between knee extensor muscle weakness and osteoarthritis (OA) outcomes has been well-studied. Muscle power, another measure of knee extensor function, however, has…
Abstract Number: 0724 • ACR Convergence 2021
Dose (Exposure) Efficacy Response of Tanezumab Following Intravenous and Subcutaneous Administration Across Phase 2 and Phase 3 Studies in Patients with Osteoarthritis of Hip and Knee
Martin Boucher¹, Kenneth Verburg², Puneet Gaitonde² and Scott marshall¹, ¹Pfizer R&D Ltd., Sandwich, United Kingdom, ²Pfizer Inc., Groton, CT
Background/Purpose: Tanezumab is a humanized monoclonal antibody against nerve growth factor that has been evaluated for relief of chronic osteoarthritis pain by subcutaneous (SC) or…
Abstract Number: 0852 • ACR Convergence 2021
Bone Marrow Lesion Segmentation Using Synthetic Data and Deep Learning Models
Barak Michaely¹, Ming Zhang² and Juan Shan¹, ¹Pace University, New York, NY, ²Wentworth Institute of Technology, Boston, MA
Background/Purpose: Bone marrow lesions (BML) are indicators for knee osteoarthritis (OA) and can be detected from magnetic resonance imaging (MRI). Due to the small size,…
Abstract Number: 1121 • ACR Convergence 2021
Association of Healthcare Costs and Utilization with Increasing Severity of Pain in Osteoarthritis Patients: An 18-Year Retrospective Study
Jove Graham¹, Tonia Novosat¹, Haiyan Sun¹, Brian Piper¹, Joseph Boscarino¹, Melissa Kern¹, Vanessa Duboski¹, Eric Wright¹, Craig Beck², Rebecca Robinson³, Edward Casey⁴, Jerry A. Hall³ and Patricia Schepman⁴, ¹Geisinger, Danville, PA, ²Pfizer, Inc., London, ³Eli Lilly and Company, Indianapolis, IN, ⁴Pfizer, Inc., New York, NY
Background/Purpose: Osteoarthritis (OA) is a disease with complex pathogenesis, and it is important to understand a patient's level of severity in order to plan and…
Abstract Number: 1447 • ACR Convergence 2021
Long-Term Effect of Prescription Non-Steroidal Anti-Inflammatory Drug Regular Use on the Risk of a Knee Replacement
S. Reza Jafarzadeh¹, Tuhina Neogi¹ and David Felson², ¹Boston University School of Medicine, Boston, MA, ²Boston University, Boston, MA
Background/Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) are a primary treatment for osteoarthritis (OA). It is uncertain, however, whether regular use of NSAIDs affects the risk of…
Abstract Number: 1903 • ACR Convergence 2021
Does Limited Stair Climbing Lead to Poor Future Health? The Relationship Between Short-term Trajectories of Stair Climbing Frequency and Incident Slow Gait Speed over 1 and 2 Years in Adults with Knee Osteoarthritis
Jason Jakiela¹, Yuqing Zhang², Dana Voinier¹, Thomas Bye¹, Jennifer Copson¹ and Daniel White¹, ¹University of Delaware, Newark, DE, ²Massachusetts General Hospital, Quincy, MA
Background/Purpose: Knee osteoarthritis (OA) is a common cause of functional limitation in older adults, and difficulty with climbing stairs is one of the first limitations…
Abstract Number: 0222 • ACR Convergence 2021
Effects of Multi-Joint Osteoarthritis Phenotypes on Self-Reported Physical Function over 3.5 Years: The Johnston County Osteoarthritis Project
Amanda Nelson¹, Carolina Alvarez¹, Liubov Arbeeva¹, Jordan Renner¹, Virginia Kraus², Duncan Lascelles³ and Yvonne Golightly¹, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Duke University, Durham, NC, ³North Carolina State University, Raleigh, NC
Background/Purpose: To determine the differential effects of several literature-based definitions of multi-joint osteoarthritis (MJOA) on change in self-reported physical function in a community-based cohort.Methods: We…
Abstract Number: 0725 • ACR Convergence 2021
Efficacy of Subcutaneous Tanezumab for the Treatment of Osteoarthritis of the Knee or Hip: A Post Hoc Subgroup Analysis of Patients from a Randomized, NSAID-Controlled Study with a History of Depression, Anxiety, or Insomnia
Philip Mease¹, Theresa Mallick-Searle², Elizabeth Johnston³, Lars Viktrup³, Dominique Menuet⁴, Ruoyong Yang⁵ and Robert Fountaine⁶, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²Stanford Health Care, Redwood City, ³Eli Lilly and Company, Indianapolis, IN, ⁴Pfizer SAS, Paris, France, ⁵Pfizer Inc., New York, NY, ⁶Pfizer Inc., Groton, CT
Background/Purpose: Tanezumab is a monoclonal antibody directed against nerve growth factor that is under study to treat moderate to severe chronic pain associated with osteoarthritis…
Abstract Number: 0940 • ACR Convergence 2021
Overactivation of the Kinase IKK2 Causes a Hand Osteoarthritis-Like Phenotype in Mice
Sergio Ramirez-Perez, kyle Jones, Umesh Gangishetti and Pallavi Bhattaram, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Hand osteoarthritis (OA) presents the highest prevalence among rheumatic diseases. Synovitis is a defining feature in hand OA that has been associated with radiographic…
Abstract Number: 1122 • ACR Convergence 2021
Patient-perceived Solutions to the Treatment Barriers in Knee Osteoarthritis: A Qualitative Study from a Diverse Patient Group Including Racial/ethnic Minorities
Jasvinder Singh, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Knee osteoarthritis (OA) has worse outcomes in racial/ethnic minorities. Yet, most of the qualitative studies include primarily Caucasian people with knee OA, with minimal…
Abstract Number: 1456 • ACR Convergence 2021
Cannabidiol Treatment in Hand Osteoarthritis and Psoriatic Arthritis – A Randomized, Double-blind Placebo-controlled Trial
Jonathan Vela¹, Salome Kristensen², Lene Dreyer², Kristian Kjær Petersen³ and Lars Arendt Nielsen³, ¹Dept. of Rheumatology Aalborg Denmark, Aalborg, Denmark, ²Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ³Aalborg University, Aalborg, Denmark
Background/Purpose: Medical cannabis is increasing in popularity yet the recent International Association for the Study of Pain presidential task force on cannabis and cannabinoid analgesia…
Abstract Number: 1904 • ACR Convergence 2021
“Why Does My Knee Hurt After I Got My Knee Replaced?”: Evaluation of Neuropathic-like Symptoms and Objective Signs of Neuropathy Post-Knee Replacement in Patients with Knee Osteoarthritis
Devin Driscoll¹, Priyanka Ballal¹, Na Wang², Laura Frey-Law³, Cora Lewis⁴, Michael Nevitt⁵ and Tuhina Neogi¹, ¹Boston University School of Medicine, Boston, MA, ²Boston University, Boston, MA, ³University of Iowa, Iowa City, IA, ⁴University of Alabama Birmingham, Birmingham, AL, ⁵University of California San Francisco, Orinda, CA
Background/Purpose: Some people with knee osteoarthritis (OA) have persistent pain post-knee replacement, but why this occurs is not fully understood. One possibility is post-surgical neuropathy.…
Abstract Number: 0011 • ACR Convergence 2021
Differential Inflammation-mediated Function of Prokineticin 2 in the Synovial Fibroblasts of Patients with Rheumatoid Arthritis Compared to Osteoarthritis
Kentaro Noda, Bianca Dufner and Rainer Straub, Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, Department of Internal Medicine I, University Hospital Regensburg, Regensburg, Germany
Background/Purpose: Prokineticin 2 (PK2) is a secreted protein involved in several pathological and physiological processes, including the regulation of inflammation, sickness behaviors, and the circadian…
Abstract Number: 0223 • ACR Convergence 2021
The Association of Clinical and Structural Knee Osteoarthritis with Physical Activity in the Middle-aged Population: The Netherlands Epidemiology of Obesity Study
Sietse Terpstra¹, Jeroen van der Velde¹, Renée de Mutsert¹, Dieuwke Schiphof², Monique Reijnierse¹, Frits Rosendaal¹, Lotte van de Stadt¹, Margreet Kloppenburg¹ and Marieke Loef¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: Physical activity is a potential target for interventions in knee OA. However, most of the available studies concerning physical activity in individuals with knee…
Abstract Number: 0726 • ACR Convergence 2021
Joint Safety of Tanezumab versus NSAIDs; A Combined Assessment of Benefit and Harm
Robert Fountaine¹, Robert Dworkin², Anne Hickman¹, Glenn Pixton³, Ed Whalen⁴, Christine West¹ and Kenneth Verburg¹, ¹Pfizer Inc., Groton, CT, ²University of Rochester, Rochester, NY, ³Pfizer Inc., Morrisville, NC, ⁴Pfizer Inc., New York, NY
Background/Purpose: Tanezumab, a monoclonal antibody against nerve growth factor, is in development for the relief of signs and symptoms of moderate to severe osteoarthritis (OA)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].